Method for extracting and purifying mesenchymal stem cells
Through ultrasonic assisted digestion, dual filtration system, negative selection of immune magnetic beads and high-performance liquid separation technology, combined with quality control, the problems of cell heterogeneity and low purity in the extraction and purification of mesenchymal stem cells in the existing technology are solved, and the problem of low cell heterogeneity and purity is achieved. Highly efficient and highly purified cell extraction and purification, complying with international standards.
Patent Information
- Application Number
- CN202411308983.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-19
- Publication Date
- 2024-11-12
AI Technical Summary
Existing methods for extracting and purifying mesenchymal stem cells from adipose tissue have problems of cell heterogeneity, low purity and inconsistent function.
Ultrasonic assisted digestion, dual filtration system, negative selection of immunomagnetic beads and high-performance liquid phase separation technology are used, combined with strict quality control, and mesenchymal stem cells are extracted and purified.
It significantly improves cell purity and recovery, ensures cell functional consistency and pluripotency, and complies with international cell therapy standards such as MISEV2018 and GMP standards.
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a method for extracting and purifying mesenchymal stem cells. Background Art
[0002] Mesenchymal stem cells have broad application prospects in the fields of regenerative medicine, tissue engineering and cell therapy due to their self-renewal ability, multidirectional differentiation potential and immunomodulatory properties. Adipose tissue is one of the important sources of mesenchymal stem cells.
[0003] Traditional methods for extracting and purifying mesenchymal stem cells from adipose tissue include density gradient centrifugation and immunomagnetic bead sorting. Density gradient centrifugation is used to sort different cells in the bone marrow based on their size and density differences. The bone marrow cell suspension is added to the density gradient centrifuge fluid, and different types of cells are centrifuged to settle to their isodensity points, and then the cells enriched in specific locations are aspirated. The immunomagnetic bead sorting method separates cells based on the principle that cell surface antigens can bind to specific monoclonal antibodies connected to magnetic beads. In an external magnetic field, cells connected to magnetic beads through antibodies are adsorbed and retained in the magnetic field. Cells without such surface antigens have no magnetism because they cannot bind to specific monoclonal antibodies connected to magnetic beads, and do not stay in the magnetic field, thereby separating the cells.
[0004] Although the above two methods can extract and purify mesenchymal stem cells to a certain extent, there are problems such as cell heterogeneity, low purity and inconsistent functions. Summary of the invention
[0005] In order to solve the problems of cell heterogeneity, low purity and inconsistent functions in existing methods for extracting and purifying mesenchymal stem cells, the present invention proposes an innovative method for extracting and purifying mesenchymal stem cells from adipose tissue by introducing ultrasonic-assisted digestion, double filtration system, immunomagnetic bead sorting and high-performance liquid separation technology.
[0006] To achieve the above purpose, the present invention adopts the following technical solution.
[0007] The present invention provides a method for extracting and purifying mesenchymal stem cells. The present invention introduces ultrasonic technology in the digestion step, which improves the digestion efficiency while reducing the enzyme dosage and time, and reduces cell damage. In addition, the cell purity is further improved by a double filtration system and high-efficiency liquid separation technology. Finally, through strict quality control, it is ensured that the extracted mesenchymal stem cells meet international cell therapy standards such as MISEV2018 and GMP standards, which is conducive to clinical application and achievement transformation. The mesenchymal stem cells extracted by the method proposed by the present invention do not have cell heterogeneity, and significantly improve cell purity and recovery rate, and ensure consistent cell function, as well as cell pluripotency and consistency with international standards. Among them, the English abbreviation of mesenchymal stem cells is MSCs.
[0008] Specifically, the method for extracting and purifying mesenchymal stem cells provided by the present invention comprises the following steps:
[0009] (1) Collection and preparation of adipose tissue: Adipose tissue was collected from the abdomen of volunteers, washed four times with pre-cooled PBS buffer to remove blood and impurities, and the washed adipose tissue was cut into approximately 1 mm 3 to obtain the prepared adipose tissue.
[0010] (2) Ultrasonic-assisted digestion: Under a sterile environment, prepare an enzymatic solution containing 0.05% to 0.1% collagenase I by volume and 0.005% to 0.02% neutral protease by volume, and preheat to 36°C to 38°C. Place the prepared adipose tissue into the enzymatic solution to form a mixed solution. Perform ultrasonic-assisted digestion of the mixed solution at 36°C to 38°C. Set the ultrasonic frequency to 39kHz to 41kHz, the processing time to 18 minutes to 22 minutes, and gently shake the mixed solution every 4.5 minutes to 5.5 minutes to ensure uniform digestion.
[0011] The mass ratio of the prepared adipose tissue to the volume of the enzymatic hydrolysate is: 0.9 g to 1.1 g: 10 mL.
[0012] (3) Double filtration system: The digested mixture is double filtered through a microporous filter membrane and an ultrafiltration system to remove large tissue fragments and blood cells, and then resuspended in PBS to obtain a preliminary purified cell suspension.
[0013] (4) Immunomagnetic negative selection: The initially purified cell suspension obtained after purification by the double filtration system is incubated with anti-CD45 magnetic beads and anti-CD31 magnetic beads at 3.9°C to 4.1°C for 25 minutes to 35 minutes. The blood cells and endothelial cells in the cell suspension are removed by immunomagnetic negative selection technology to obtain a cell suspension that is not bound to magnetic beads. Immunomagnetic negative selection is a type of immunomagnetic bead sorting method. Immunomagnetic bead sorting methods are divided into positive selection and negative selection. In the positive selection method, the cells bound to the magnetic beads are the cells to be separated; in the negative selection method, the magnetic beads bind to the unwanted cells, and the cells free in the supernatant are the desired target cells.
[0014] Among them, the mass ratio of the preliminary purified cell suspension obtained after purification by the double filtration system to the anti-CD45 magnetic beads and anti-CD31 magnetic beads was 1:20:20.
[0015] (5) High performance liquid separation: incubate the cell suspension not bound to magnetic beads with anti-CD73 antibody, anti-CD90 antibody and anti-CD105 antibody at 36°C to 38°C for 38 minutes to 32 minutes to obtain a labeled cell suspension; separate the labeled cell suspension by a high performance liquid chromatography system to obtain high-purity mesenchymal stem cells.
[0016] Among them, the mass ratio of the cell suspension not bound to magnetic beads to anti-CD73 antibody, anti-CD90 antibody and anti-CD105 antibody was 1:100:100:100.
[0017] (6) Cell quality control: Use flow cytometry to detect cell surface markers and verify cell viability and differentiation potential to ensure the pluripotency and functionality of the cells.
[0018] Preferably, the enzymatic hydrolysis solution is an enzymatic hydrolysis solution containing 0.075% by volume of collagenase I and 0.01% by volume of neutral protease.
[0019] Preferably, the conditions for ultrasound-assisted digestion are: the ultrasound frequency is set to 40 kHz, the treatment time is 20 minutes, and mixing is performed every 5 minutes during the treatment process.
[0020] Preferably, the double filtration using a microporous filter membrane and an ultrafiltration system refers to double filtration of the digested mixed solution using two filter membranes with successively decreasing pore diameters, and then centrifuging the cell suspension collected after filtration.
[0021] The diameters of the filter pores of the two filter membranes are 60 μm to 80 μm and 30 μm to 40 μm respectively.
[0022] Preferably, the pore diameters of the filter membrane used in the double-layer filtration are 70 μm and 40 μm; and the centrifugal conditions are 400×g for 5 minutes.
[0023] Preferably, the conditions for incubation after the preliminary purified cell suspension obtained after purification by the double filtration system is mixed with the anti-CD45 magnetic beads and the anti-CD31 magnetic beads are incubated at 4° C. for 30 minutes;
[0024] Wherein, the mass ratio of the anti-CD45 magnetic beads to the anti-CD31 magnetic beads is 1:1.
[0025] Preferably, the cell suspension not bound to magnetic beads is mixed with anti-CD73 antibody, anti-CD90 antibody and anti-CD105 antibody and incubated at 37° C. for 30 minutes.
[0026] Among them, the mass ratio of the anti-CD73 antibody, anti-CD90 antibody and anti-CD105 antibody is 1:1:1.
[0027] Preferably, the chromatographic conditions when the high performance liquid chromatography system is separated are:
[0028] Chromatographic column: C18 reverse phase chromatographic column; mobile phase: 0.1% by mass trifluoroacetic acid aqueous solution and 0.1% by mass TFA acetonitrile solution; mobile phase flow rate: 0.8 mL / min~1.2 mL / min; detection wavelength: 215 nm~225 nm; chromatographic column temperature: 25℃~35℃.
[0029] Preferably, the labeled cell suspension needs to be subjected to sample treatment before being separated by a high performance liquid chromatography system; the sample treatment method is: resuspending the labeled cell suspension with PBS buffer and filtering to remove particulate matter.
[0030] Preferably, the concentration of the PBS buffer is 1X and the pH is 7.3-7.5.
[0031] Compared with the prior art, the present invention has the following beneficial effects:
[0032] The present invention provides a method for extracting and purifying mesenchymal stem cells, wherein the mesenchymal stem cells extracted by the method do not have cell heterogeneity, significantly improve cell purity and recovery rate, and ensure consistent cell functions, as well as cell pluripotency and international standard consistency. The key technical methods in the method provided by the present invention include ultrasonic assisted digestion technology, double filtration system, immunomagnetic bead negative selection technology, high-performance liquid phase separation technology, and cell quality control.
[0033] (1) Ultrasound-assisted digestion technology
[0034] Compared with the traditional single enzymatic method, ultrasound-assisted digestion technology significantly improves the digestion efficiency of adipose tissue, reduces the amount of enzymes and time, and reduces cell damage. The mechanical vibration of ultrasound helps collagenase and neutral protease penetrate into adipose tissue more quickly and evenly, thereby improving digestion efficiency. This method showed higher digestion efficiency and cell activity in actual operation. By optimizing ultrasound parameters and digestion time, this method achieves efficient digestion of adipose tissue, laying a solid foundation for subsequent cell extraction and purification.
[0035] (2)Dual filtration system
[0036] By combining the microporous filter membrane and the ultrafiltration system, large tissue fragments and blood cells can be effectively removed to initially obtain a pure cell suspension. This double filtration system significantly improves the purity of the initial cell suspension, providing a better foundation for subsequent immunomagnetic bead sorting and high-performance liquid separation. The double filtration design significantly reduces the impurity content in the cell suspension and improves the efficiency of subsequent purification steps. By optimizing the filtration process, this method improves the purity and quality of the cell suspension while ensuring cell viability.
[0037] (3) Immunomagnetic bead negative selection technology
[0038] Negative selection technology uses markers such as CD45 and CD31 for immunomagnetic negative selection to remove non-mesenchymal stem cells. Compared with positive selection technology, negative selection technology can better retain the multipotency and proliferation ability of MSCs and reduce the contamination of non-target cells. Negative selection technology not only improves the purity of mesenchymal stem cells, but also ensures the multipotency and functionality of the cells. By optimizing the negative selection conditions, this method achieves higher selectivity and efficiency in the cell purification process. Among them, the English abbreviation of mesenchymal stem cells is MSCs.
[0039] (4) High performance liquid separation technology
[0040] Through high-performance liquid separation technology, specific sorting is performed based on cell surface markers: CD73, CD90, and CD105 to further purify mesenchymal stem cells. This technology ensures that the final cell population has high purity and high activity, providing a guarantee for clinical application. Through high-performance liquid separation technology, the purity and activity of mesenchymal stem cells have been significantly improved, ensuring the safety and effectiveness of cells in clinical applications. Optimizing liquid separation parameters further improves the separation efficiency and purity of cells.
[0041] (5) Cell quality control
[0042] Flow cytometry is used to detect the surface markers of mesenchymal stem cells, and cell viability and differentiation potential are verified to ensure the pluripotency and functionality of the cells. Comprehensive quality control measures ensure the standardization and consistency of cells, in line with international cell therapy standards: MISEV2018 and GMP standards. Quality control includes not only the detection of cell surface markers, but also the verification of cell viability and multidirectional differentiation ability, ensuring the functionality and safety of cells. The quality and consistency of each batch of cells are ensured through standardized testing processes and strict quality control measures.
[0043] Through the above-mentioned improved technology, the present invention realizes the rapid and efficient extraction and purification of mesenchymal stem cells from adipose tissue. The obtained mesenchymal stem cells not only have high purity and high recovery rate, but also maintain good pluripotency and proliferation ability, which meets the international cell therapy standards. These improved technologies make the extraction and purification process of mesenchymal stem cells more efficient and stable, providing high-quality cell materials for cell therapy and regenerative medicine. The present invention not only shows excellent performance in the laboratory, but also has high feasibility and transformation potential in practical applications. DETAILED DESCRIPTION
[0044] The following will be combined with the specific embodiments of the present invention to clearly and completely describe the technical solutions in the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0045] The methods described in the embodiments of the present invention are conventional methods unless otherwise specified. The materials, reagents, etc. used can be obtained from commercial sources unless otherwise specified.
[0046] The invention provides a method for extracting and purifying mesenchymal stem cells, comprising the collection and preparation of adipose tissue, ultrasonic-assisted digestion, a double filtration system, immunomagnetic bead negative selection, high-performance liquid separation technology and cell quality control.
[0047] The present invention uses human adipose tissue as raw material to extract and purify mesenchymal stem cells, and significantly improves cell purity and recovery rate through ultrasonic-assisted digestion, double filtration system, immunomagnetic bead negative selection and high-performance liquid separation technology.
[0048] Example 1
[0049] 1. Collection and preparation of adipose tissue
[0050] 1. Sample collection: About 10g of adipose tissue was collected from the abdomen of volunteers through minimally invasive liposuction to reduce damage to the donor.
[0051] Among them, (1) the "volunteers for collecting adipose tissue" in the embodiments of the present invention are all from certified medical institutions that have the legal qualifications for collecting human samples and conducting research. All volunteers voluntarily signed the informed consent form in accordance with the principles of the Declaration of Helsinki after fully understanding the purpose, process, potential risks and benefits of the experiment.
[0052] 1) The selection of volunteers follows the following criteria:
[0053] The age range is 18 to 60 years old.
[0054] There was no history of serious cardiovascular disease, diabetes, autoimmune disease, or other diseases that might affect the characteristics of adipose tissue.
[0055] No medication or treatment that may affect adipose tissue metabolism was received in the past 3 months.
[0056] BMI less than 18.5 kg / m 2 ~30kg / m 2 The Chinese name of BMI is body mass index.
[0057] 2) Before the fat tissue was collected, all volunteers underwent a comprehensive physical examination and were assessed by professional doctors to see if their health conditions met the experimental requirements. The collection process was performed by experienced plastic surgeons using minimally invasive liposuction under local anesthesia to reduce damage and discomfort to the donor.
[0058] 3) After the adipose tissue samples are collected, they are immediately labeled, the volunteer's number, age, gender, BMI and basic information are recorded, and they are stored at low temperatures to ensure the quality of the samples and the accuracy of subsequent experiments.
[0059] (2) The operating steps of minimally invasive liposuction are as follows:
[0060] 1) Preoperative preparation:
[0061] Volunteers complete all necessary health checks and laboratory tests to ensure they are eligible for surgery.
[0062] The volunteers signed an informed consent form and performed necessary preoperative preparations before the operation, including fasting, bathing and other routine procedures.
[0063] The surgical area is thoroughly cleaned and disinfected using rubbing alcohol or iodine solution.
[0064] 2) Anesthesia and analgesia:
[0065] The volunteers were given local anesthesia, usually using local anesthetic drugs such as lidocaine, to reduce pain during the procedure.
[0066] If necessary, appropriate amounts of analgesics can be given to ensure that volunteers remain comfortable during the operation.
[0067] 3) Surgical procedures:
[0068] The doctor uses a marker to mark the predetermined surgical area: the abdomen to determine the scope of liposuction.
[0069] Use a sterile scalpel to make a small incision of 1 cm in the marked area.
[0070] Insert the minimally invasive liposuction equipment: liposuction needle and liposuction tube into the incision and connect them to the negative pressure suction device.
[0071] Under the action of negative pressure, the liposuction needle moves repeatedly in the fat layer to break up the fat tissue and suck it out. During the operation, you need to keep your movements gentle to avoid damaging the surrounding tissues.
[0072] Adjust the vacuum intensity and the depth of the liposuction needle as needed to ensure uniform and thorough extraction of fat tissue.
[0073] Monitor the volunteers' vital signs, such as heart rate, blood pressure, etc., to ensure the safety of the operation.
[0074] 4) Postoperative treatment:
[0075] After the extraction is completed, stop the negative pressure suction immediately and carefully pull out the liposuction instrument.
[0076] The surgical incision is sutured and covered with a sterile dressing to prevent infection and bleeding.
[0077] Provide volunteers with appropriate postoperative care instructions, including diet, rest, and wound care.
[0078] Record key parameters during the operation, such as the amount of fat extracted, operation time, blood loss, etc.
[0079] 5) Sample processing and storage:
[0080] The collected adipose tissue was immediately transferred to a sterile container to avoid contamination.
[0081] The necessary processing of the fat tissue is performed, such as removing blood and cleaning.
[0082] The processed adipose tissue was divided into appropriate small portions and stored in a -80°C refrigerator for subsequent experimental use.
[0083] 2. Tissue washing: Wash the collected adipose tissue four times with pre-cooled phosphate buffered saline (PBS) solution to remove blood and impurities. Keep the washed adipose tissue at -80°C to ensure cell activity.
[0084] Among them, phosphate buffered saline solution is also called PBS buffer, which comes from Gibco, has a concentration of 1X and a pH of 7.4.
[0085] 3. Tissue cutting: Cut the cleaned fat tissue into pieces of about 1 mm 3 small pieces to increase digestion area and efficiency and obtain prepared adipose tissue.
[0086] It should be noted that excessive operation should be avoided during the cutting process to reduce cell damage.
[0087] 2. Ultrasound-assisted digestion
[0088] 1. Preparation of enzymatic solution: Under a sterile environment, prepare an enzymatic solution containing 0.075% collagenase I and 0.01% neutral protease by volume, and preheat to 37°C.
[0089] Among them, collagenase I was from Sigma, product number C0130, and neutral protease was from Roche, product number 10103578001.
[0090] 2. Ultrasonic treatment: Place 10 g of the prepared adipose tissue into 100 mL of enzymatic hydrolysate and perform ultrasonic-assisted digestion at 37°C. The ultrasonic frequency is set to 40 kHz and the treatment time is 20 minutes. Gently shake the mixture every 5 minutes to ensure uniform digestion. After digestion, centrifuge to obtain the digested cell suspension.
[0091] The centrifugal conditions were 800 rpm and 10 min.
[0092] 3. Double Filtration and Preliminary Purification
[0093] 1. Filtration: First, filter the digested cell suspension using a 70μm filter membrane to remove larger particles of impurities. Then, further filter using a 40μm filter membrane to remove incompletely digested tissue fragments and large cell impurities to ensure that the cells in the suspension have a high purity. Most of the impurities in the filtered cell suspension obtained after filtration are removed.
[0094] 2. Centrifugation: Centrifuge the filtered cell suspension at 400 × g for 5 minutes, collect the precipitate and resuspend it with PBS to obtain the preliminary purified cell suspension obtained after purification by the double filtration system.
[0095] It should be noted that the centrifugal force and time should be strictly controlled during the centrifugation process to avoid cell damage.
[0096] The PBS buffer was from Gibco, with a concentration of 1X and a pH of 7.4.
[0097] 4. Immunomagnetic Negative Selection
[0098] 1. Labeled antibodies: The preliminarily purified cell suspension obtained after purification by the double filtration system was incubated with anti-CD45 magnetic beads and anti-CD31 magnetic beads at 4°C for 30 minutes to ensure that the antibodies are fully bound to the target cells.
[0099] Among them, the mass ratio of the cell suspension obtained after purification by the double filtration system to the anti-CD45 and anti-CD31 magnetic beads was 1:20:20.
[0100] The mass ratio of anti-CD45 magnetic beads to anti-CD31 magnetic beads was 1:1.
[0101] 2. Magnetic separation: Place the incubated mixture in a magnetic field to remove the magnetic beads labeled with non-target cells and collect the cell suspension that is not bound to the magnetic beads.
[0102] The above steps significantly improve the purity of the cell suspension.
[0103] 5. High Performance Liquid Separation
[0104] 1. Cell labeling: Use anti-CD73 antibody, anti-CD90 antibody and anti-CD105 antibody to label cell surface markers, and detect and sort by flow cytometry.
[0105] The specific steps are as follows: First, the cell suspension not bound to magnetic beads is incubated with anti-CD73 antibody, anti-CD90 antibody and anti-CD105 antibody at 37°C for 30 minutes to ensure that the antibody is fully bound to the cells to obtain a labeled cell suspension.
[0106] It should be noted that the antibody concentration and incubation time should be strictly controlled during the labeling process.
[0107] Among them, the mass ratio of the cell suspension not bound to magnetic beads to anti-CD73 antibody, anti-CD90 antibody and anti-CD105 antibody was 1:100:100:100.
[0108] The mass ratio of anti-CD73 antibody, anti-CD90 antibody and anti-CD105 antibody was 1:1:1.
[0109] 2. Liquid phase separation: The labeled cell suspension is passed through a high-performance liquid phase separation system to obtain high-purity mesenchymal stem cells, which are abbreviated as MSCs.
[0110] Among them, the method for the high performance liquid separation system is as follows:
[0111] (1) Sample processing: Resuspend the labeled cell suspension in PBS buffer to a concentration of 5×10 6 cells / mL, and filtered through a 0.22 μm microporous filter membrane to remove particulate matter to obtain a processed labeled cell suspension sample.
[0112] The PBS buffer was from Gibco, with a concentration of 1X and a pH of 7.4.
[0113] (2) Loading: Load the processed and labeled cell suspension sample into the HPLC separation system. In this step, the cell suspension is introduced into the separation system and prepared for separation.
[0114] (3) Sorting: Mesenchymal stem cells are separated from other cells by a high-performance liquid separation system based on the interaction between antibodies labeled on the cell surface and a specific capture medium. This process is usually based on physical properties of cells such as size and shape and / or biological properties such as expression of surface markers.
[0115] Among them, the high performance liquid separation system is as follows:
[0116] 1) Chromatographic column:
[0117] Type: C18 reverse phase column.
[0118] Dimensions: Length 150mm, inner diameter 4.6mm, column packing particle size 5μm.
[0119] 2) Mobile phase composition:
[0120] Mobile phase A: 0.1% by mass trifluoroacetic acid aqueous solution.
[0121] Mobile phase B: 0.1% by mass TFA acetonitrile solution.
[0122] 3) Gradient program:
[0123] From 0 to 10 minutes, the volume percentage of mobile phase B increased linearly from 10% to 40%.
[0124] From 10 to 20 minutes, the mobile phase B was linearly increased from 40 volume % to 70 volume %.
[0125] For 20 to 30 minutes, the volume percentage of mobile phase B was maintained at 70%.
[0126] 4) Flow rate: 1.0 mL / min.
[0127] 5) Column temperature: 30°C.
[0128] 6). Detector settings:
[0129] Detector Type: UV detector.
[0130] Detection wavelength: 220nm.
[0131] 7) Injection volume:
[0132] Injection volume: 20 μL.
[0133] 8) Detection time: 30 minutes.
[0134] (4) Collection: Collect the separated mesenchymal stem cell suspension. The mesenchymal stem cells in the mesenchymal stem cell suspension should have high purity, that is, most of the cells are mesenchymal stem cells and have good cell activity.
[0135] After high-performance liquid separation, the purity of the obtained mesenchymal stem cell population can reach 98.9%, and the cell activity is strong, as shown by a high proportion of living cells, high levels of ATP content and rapid proliferation rate. These high-quality mesenchymal stem cells provide reliable cell materials for subsequent cell therapy, tissue engineering and regenerative medicine research. After high-performance liquid separation, the purity of the obtained mesenchymal stem cell population can reach more than 98.9%, and the cell activity is strong, as shown by a high proportion of living cells, high levels of ATP content and rapid proliferation rate. These high-quality mesenchymal stem cells provide reliable cell materials for subsequent cell therapy, tissue engineering and regenerative medicine research.
[0136] VI. Cell Quality Control
[0137] 1. Flow cytometry: Detect the expression of surface markers of mesenchymal stem cells extracted above: CD73, CD90, CD105 to ensure the purity and characteristics of MSC. The test results must meet international cell therapy standards. The specific steps are as follows:
[0138] 1) Sample preparation: Adjust the isolated mesenchymal stem cell suspension to a concentration of 1×10 6 cells / mL for detection.
[0139] 2) Labeled antibodies: fluorescently labeled anti-CD73, anti-CD90 and anti-CD105 antibodies are incubated with the above-adjusted concentration of the cell suspension, and the flow cytometer is operated according to the requirements.
[0140] 3) On-machine testing: Analyze the expression of cell surface markers through flow cytometer software to evaluate the purity and characteristics of cells.
[0141] 4) Result analysis: Based on the test results, determine whether the purity and characteristics of the cells meet international cell therapy standards.
[0142] The test results showed that the expression levels of CD73, CD90, and CD105 were 98.5% for CD73, 99.0% for CD90, and 98.8% for CD105. These expression levels were significantly higher than the thresholds specified in the international cell therapy standards, which fully demonstrated that the extracted mesenchymal stem cells had a high degree of purity and characteristics, meeting or even exceeding the international cell therapy standards. Among them, the threshold specified in the international cell therapy standards is usually ≥95%.
[0143] For example, the expression levels of CD73, CD90, and CD105 should be within a certain range to indicate that the cells have high purity and characteristics.
[0144] The above test results indicate that the mesenchymal stem cells in the above separated mesenchymal stem cell suspension have high purity and characteristics.
[0145] 2. Cell viability detection: Use CCK-8 method to detect the cell viability of the mesenchymal stem cells obtained in advance to ensure the cell proliferation ability. Viability detection is an important indicator for evaluating cell functionality. The specific operation steps are as follows:
[0146] 1) Prepare cell suspension: adjust the concentration of the isolated mesenchymal stem cell suspension to 2×10 5 cells / mL.
[0147] 2) Inoculating cells: Inoculate the cell suspension after adjusting the concentration into a 96-well plate, add 50 μL of the cell suspension to each well to ensure that the cells are evenly distributed.
[0148] 3) Cultivation: The inoculated cells were cultured at 37°C and 5% CO2 for 24 hours.
[0149] Add CCK-8 reagent: According to the instructions of the CCK-8 kit, add CCK-8 reagent to each well and continue culturing for 2 hours.
[0150] 4) Determine absorbance: Use an ELISA reader to measure the absorbance of each well at 450 nm, and calculate the cell viability based on the absorbance value.
[0151] According to the absorbance value measured by the microplate reader at 450nm, by comparing the absorbance value of the experimental group with that of the blank group, it was calculated that the cell viability of the experimental group was 120% of that of the blank group, indicating that the cells in the experimental group had higher proliferation activity.
[0152] The experimental group was the test for the mesenchymal stem cells obtained in advance; the blank group was the test for the PBS buffer.
[0153] The above detection results show that the mesenchymal stem cells in the above separated mesenchymal stem cell suspension have higher cell activity.
[0154] 3. Verification of differentiation potential: The obtained high-purity mesenchymal stem cells are cultured for osteogenic, adipogenic and chondrogenic induction to verify their multidirectional differentiation ability. Verification of differentiation potential is an important step to ensure cell pluripotency.
[0155] The steps of osteogenic differentiation are as follows:
[0156] 1) Prepare cells: adjust the isolated mesenchymal stem cell suspension to a concentration of 1×10 5 cells / mL and inoculated them into culture dishes.
[0157] 2) Inducing differentiation:
[0158] S1. Preparation of osteogenic induction medium:
[0159] DMEM basal medium was used, and 10% FBS, 100 nM dexamethasone, 10 mM sodium β-glycerophosphate, and 50 μg / mL ascorbic acid were added. The Chinese name of FBS is fetal bovine serum.
[0160] S2. Inducing differentiation operation:
[0161] Remove the culture medium and gently wash the cells once with PBS buffer.
[0162] Add osteogenic induction medium to the dish, ensuring that all cell surfaces are covered.
[0163] The culture dish was placed in a cell culture incubator at 37°C and 5% CO2.
[0164] Fresh osteogenic induction medium was replaced every 3 days.
[0165] After 3 weeks of induction culture, the osteogenic differentiation effect was evaluated by alkaline phosphatase staining.
[0166] The steps for adipogenic differentiation are as follows:
[0167] S1. Preparation of adipogenic induction medium:
[0168] DMEM basal medium was used, and 10% FBS, 1 μM dexamethasone, 0.5 mM IBMX, 10 μg / mL insulin, and 200 μM indomethacin were added. The Chinese name of IBMX is 3-isobutyl-1-methylxanthine.
[0169] S2. Inducing differentiation operation:
[0170] Similar to the above osteogenic differentiation procedure, the original culture medium was removed and the cells were washed with PBS buffer.
[0171] Add adipogenic induction medium and place in the incubator.
[0172] After 3 days of induction, the culture medium was replaced with DMEM containing only 10% FBS and 10 μg / mL insulin, and the culture was continued for 1 day. This process is called the "differentiation period".
[0173] Repeat the steps of "induction phase" and "differentiation phase" 3 times.
[0174] Finally, the cells were cultured in DMEM basal medium containing only 10% FBS by mass until lipid droplets were formed.
[0175] Oil red O staining was used to detect lipid droplet formation and evaluate the adipogenic differentiation effect.
[0176] The steps for chondrogenic differentiation are as follows:
[0177] Chondrogenic induction is usually performed in three-dimensional culture systems, using either micromass culture or alginate bead systems.
[0178] S1. Preparation of chondrogenic induction medium:
[0179] Use DMEM basal medium, add 1% ITS+Premix (insulin, transferrin, selenide mixture), 10ng / mL TGF-β3 (transforming growth factor-β3), 100nM dexamethasone, 50μg / mL ascorbic acid, and 1% FBS. Premix is a mixture of insulin, transferrin, and selenide. The mass ratio of insulin, transferrin, and selenide in the mixture is 1:1:1.
[0180] S2. Inducing differentiation operation:
[0181] Inoculate the culture dish when it reaches high density, that is, close to confluence.
[0182] The original culture medium was removed and the cells were washed with PBS buffer.
[0183] Add chondrogenic induction medium and place in the incubator.
[0184] Fresh culture medium was replaced every 3 days.
[0185] After 4 weeks of induction, the chondrogenic differentiation was evaluated by toluidine blue staining or type II collagen immunohistochemical staining.
[0186] 3) Observation and record: During the induction culture process, regularly observe the morphological changes and growth of cells and record the relevant data.
[0187] 4) For example, osteogenic induction can observe the formation of calcium deposits, adipogenic induction can observe the formation of lipid droplets, and chondrogenic induction can observe the formation of cartilage matrix.
[0188] 5) Result analysis: Based on the observed results, the multidirectional differentiation ability of the cells was evaluated.
[0189] Among them, the observation records of osteogenic differentiation are as follows:
[0190] ① Observation time point: set a fixed observation time point, observe every 3 days, and record the entire process from the beginning to the end of induction.
[0191] ② Cell morphology observation:
[0192] Use an inverted microscope to observe the cell distribution and morphological changes in the entire culture dish at low power, and record whether there are cell aggregation, morphological changes, etc.
[0193] Switch to a high-power microscope and carefully observe the morphology of individual cells, paying attention to whether the cell boundaries are clear, whether there are protrusions formed, etc.
[0194] ③Observation of osteogenic differentiation markers:
[0195] After 2 weeks of induction, special attention was paid to whether there were signs of calcium deposition. Mineralized nodules on the cell layer were observed using phase contrast microscopy.
[0196] Alkaline phosphatase staining was performed to directly observe ALP activity as an early indicator of osteogenic differentiation.
[0197] After 4 weeks of induction culture, Alizarin red staining was performed to observe the formation of calcium deposition, which is a late sign of osteogenic differentiation.
[0198] ④Record data:
[0199] The date, time and observed phenomena of each observation, cell morphology changes, and the time and number of mineralized nodules were recorded.
[0200] If a staining experiment is performed, photos should be taken to record the staining results, and the area or number of mineralized nodules should be measured for quantitative analysis.
[0201] The observations of adipogenic differentiation were recorded as follows:
[0202] ① Observation time point: also set a fixed observation time point, observe every 3 days, and record the entire induction differentiation process.
[0203] ① Cell morphology observation:
[0204] Observe whether the cell morphology gradually changes from long spindle to round or polygonal, which is a sign of adipocyte differentiation.
[0205] Pay attention to whether lipid droplets are formed in the cells. Usually, lipid droplets appear as bright dots in the cells.
[0206] ①Observation of adipogenic differentiation markers:
[0207] After 3 weeks of induction culture, Oil Red O staining was performed to observe the formation of lipid droplets. Oil Red O can bind to neutral fat and stain it bright red, thus clearly showing the lipid droplets.
[0208] ④Record data:
[0209] The date, time, cell morphology and lipid droplet formation of each observation were recorded.
[0210] Take photos to record the Oil Red O staining results, and count the number or area of lipid droplets for quantitative analysis.
[0211] The observations of chondrogenic differentiation were recorded as follows:
[0212] ①Observation time point: regular observation, once a week.
[0213] ② Cell morphology observation:
[0214] Observe whether the cells form dense clumps of cells, which is a sign that chondrocytes are beginning to aggregate.
[0215] Note whether the cell morphology gradually changes from spindle to round or polygonal, and whether the intercellular spaces decrease.
[0216] ③Observation of cartilage differentiation markers:
[0217] After 3 weeks of induction culture, toluidine blue staining or type II collagen immunohistochemical staining was performed to observe the formation of cartilage matrix. Toluidine blue can stain acidic mucopolysaccharides into blue-purple.
[0218] ④Record data:
[0219] The date, time, cell morphology changes and cartilage matrix formation of each observation were recorded.
[0220] The staining results can be recorded by taking photos, and the staining intensity and distribution range can be evaluated for quantitative analysis.
[0221] After the above detailed differentiation induction experimental steps and observation records, the present invention evaluated the multidirectional differentiation ability of the above mesenchymal stem cells. The specific results are as follows:
[0222] (1) Osteogenic differentiation results:
[0223] Under the action of osteogenic induction medium, the morphology of mesenchymal stem cells gradually changed from long spindle to flat or polygonal, and cells were observed to aggregate to form mineralized nodules.
[0224] By Alizarin red staining, we observed the formation of obvious red mineralized nodules, which indicated the deposition of calcium salts and was a late sign of osteogenic differentiation.
[0225] Quantitative analysis showed that the number and area of mineralized nodules reached significant levels, indicating that mesenchymal stem cells successfully differentiated into osteoblasts.
[0226] (2) Adipogenic differentiation results:
[0227] Under the action of adipogenic induction medium, the morphology of mesenchymal stem cells changed from long spindle to round or polygonal, and bright lipid droplets appeared in the cells.
[0228] Oil Red O staining results showed that the cells were filled with lipid droplets stained bright red, further confirming the formation of lipid droplets.
[0229] Quantitative analysis showed that the number and size of lipid droplets met experimental expectations, indicating that mesenchymal stem cells successfully differentiated into adipocytes.
[0230] (3) Chondrogenic differentiation results:
[0231] We observed that mesenchymal stem cells formed dense cell clusters and that the cell morphology also changed.
[0232] Toluidine blue staining results showed that blue-purple colored areas appeared in the cell aggregates, which indicated the formation of cartilage matrix such as proteoglycan.
[0233] The above observations still indicate that mesenchymal stem cells have the potential to differentiate into chondrocytes.
[0234] In summary, according to our observations and staining analysis, mesenchymal stem cells showed obvious differentiation characteristics under osteogenic, adipogenic and chondrogenic differentiation conditions. The cells can be successfully induced to differentiate into osteoblasts, adipocytes and chondrocytes, which fully proves that mesenchymal stem cells have multidirectional differentiation ability, i.e., pluripotency. These results not only verify that the mesenchymal stem cells obtained by the extraction and purification method of the present invention maintain good biological properties, but also provide reliable cell materials for subsequent cell therapy, tissue engineering and regenerative medicine research.
[0235] In summary, the above test results indicate that the mesenchymal stem cells in the above-isolated mesenchymal stem cell suspension have multidirectional differentiation ability, that is, pluripotency.
[0236] From the above experimental results, it can be seen that: through the above improved technology, the method for extracting and purifying mesenchymal stem cells provided by the present invention can achieve rapid and efficient extraction and purification of mesenchymal stem cells from adipose tissue. The obtained mesenchymal stem cells not only have high purity and high recovery rate, but also maintain good pluripotency and proliferation ability, meet international cell therapy standards, and are conducive to clinical application and achievement transformation.
[0237] In summary, the method for extracting and purifying mesenchymal stem cells provided by the present invention provides a new and effective solution for the extraction and purification of mesenchymal stem cells, which has important scientific value and application prospects. The mesenchymal stem cells extracted by this method do not have cell heterogeneity, and significantly improve the cell purity and recovery rate, and ensure the consistency of cell function, as well as the multipotency and international standard consistency of the cells.
[0238] The present invention provides a method for extracting and purifying mesenchymal stem cells, which introduces ultrasonic technology in the digestion step, improves digestion efficiency while reducing enzyme dosage and time, and reduces cell damage. In addition, the cell purity is further improved by a double filtration system and high-efficiency liquid separation technology. Ultimately, through strict quality control, it is ensured that the extracted mesenchymal stem cells meet international cell therapy standards (such as MISEV2018 and GMP standards), which is conducive to clinical application and achievement transformation.
[0239] It should be noted that when the present invention involves a numerical range, it should be understood that the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. In order to avoid redundancy, the present invention describes a preferred embodiment.
[0240] Although preferred embodiments of the present invention have been described, those skilled in the art may make additional changes and modifications to these embodiments once the basic inventive concepts are known, and all such changes and modifications fall within the scope of the present invention.
Claims
1. A method for extracting and purifying mesenchymal stem cells, characterized in that: The method comprises the following steps: Adipose tissue collection and preparation; The prepared adipose tissue is placed in an enzymatic solution containing 0.05% to 0.1% collagenase I by volume and 0.005% to 0.02% neutral protease by volume to form a mixed solution; the mixed solution is subjected to ultrasonic-assisted digestion at 36° C. to 38° C.; the ultrasonic frequency is set to 39 kHz to 41 kHz, the processing time is 18 minutes to 22 minutes, and the mixture is mixed every 4.5 minutes to 5.5 minutes; the mass ratio of the prepared adipose tissue to the volume of the enzymatic solution is: 0.9 g to 1.1 g: 10 mL; Double filtration system: The digested mixture is double filtered through a microporous filter membrane and an ultrafiltration system to remove large tissue fragments and blood cells to obtain a preliminarily purified cell suspension; Immunomagnetic negative selection: The preliminarily purified cell suspension obtained after purification by the double filtration system is incubated with anti-CD45 magnetic beads and anti-CD31 magnetic beads at 3.9°C to 4.1°C for 25 minutes to 35 minutes, and the blood cells and endothelial cells in the cell suspension are removed by immunomagnetic negative selection technology to obtain a cell suspension not bound to magnetic beads; the mass ratio of the preliminarily purified cell suspension obtained after purification by the double filtration system to the anti-CD45 magnetic beads and anti-CD31 magnetic beads is 1:20:20; High-performance liquid separation: incubating the cell suspension not bound to magnetic beads with anti-CD73 antibody, anti-CD90 antibody and anti-CD105 antibody at 36° C. to 38° C. for 28 to 32 minutes to obtain a labeled cell suspension; separating the labeled cell suspension by a high-performance liquid chromatography system to obtain high-purity mesenchymal stem cells; The mass ratio of the cell suspension not bound to magnetic beads to anti-CD73 antibody, anti-CD90 antibody and anti-CD105 antibody was 1:100:100:
100.
2. A method for extracting and purifying mesenchymal stem cells according to claim 1, characterized in that: The enzymatic hydrolysis solution contains 0.075% collagenase I by volume and 0.01% neutral protease by volume.
3. A method for extracting and purifying mesenchymal stem cells according to claim 1, characterized in that: The conditions for ultrasound-assisted digestion were as follows: the ultrasound frequency was set at 40 kHz, the treatment time was 20 minutes, and mixing was performed every 5 minutes during the treatment.
4. A method for extracting and purifying mesenchymal stem cells according to claim 1, characterized in that: Double filtration by microporous membrane and ultrafiltration system refers to double filtration of the digested mixed solution by using two filter membranes with successively decreasing pore diameters, and then centrifuging the cell suspension collected after filtration; The pore diameters of the two filter membranes are 60 μm to 80 μm and 30 μm to 50 μm respectively.
5. A method for extracting and purifying mesenchymal stem cells according to claim 4, characterized in that: The pore diameters of the filter membranes used in the double-layer filtration were 70 μm and 40 μm, and the centrifugation conditions were 400×g for 5 minutes.
6. A method for extracting and purifying mesenchymal stem cells according to claim 1, characterized in that: The conditions for incubation of the preliminarily purified cell suspension obtained after purification by the double filtration system with anti-CD45 magnetic beads and anti-CD31 magnetic beads were 4°C for 30 minutes; Wherein, the mass ratio of the anti-CD45 magnetic beads to the anti-CD31 magnetic beads is 1:
1.
7. A method for extracting and purifying mesenchymal stem cells according to claim 1, characterized in that: The cell suspension not bound to magnetic beads was mixed with anti-CD73 antibody, anti-CD90 antibody, and anti-CD105 antibody and incubated at 37°C for 30 minutes; Among them, the mass ratio of the anti-CD73 antibody, anti-CD90 antibody and anti-CD105 antibody is 1:1:
1.
8. A method for extracting and purifying mesenchymal stem cells according to claim 1, characterized in that: The chromatographic conditions for separation by HPLC system are: Chromatographic column: C18 reverse phase column; Mobile phase: 0.1% by mass trifluoroacetic acid aqueous solution and 0.1% by mass TFA acetonitrile solution; mobile phase flow rate: 0.8 mL / min to 1.2 mL / min; detection wavelength: 215 nm to 225 nm; chromatographic column temperature: 25° C. to 35° C.
9. A method for extracting and purifying mesenchymal stem cells according to claim 1, characterized in that: The labeled cell suspension needs to be subjected to sample treatment before being separated by a high performance liquid chromatography system; The sample processing method is: resuspending the labeled cell suspension with PBS buffer and filtering to remove particulate matter.
10. A method for extracting and purifying mesenchymal stem cells according to claim 9, characterized in that: The concentration of the PBS buffer is 1×, and the pH is 7.3-7.5.
